Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression

Journal of Experimental Medicine

Volumn 209, Issue 2, 2012, Pages 217-224

  Goldberg, Michael S ^a   Sharp, Phillip A ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PYRUVATE KINASE; PYRUVATE KINASE M1; PYRUVATE KINASE M2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXON; FIBROBLAST; GENE; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; GENE KNOCKDOWN TECHNIQUES; GENE LIBRARY; GENE THERAPY; GLUCOSE; HUMANS; MICE; MICE, SCID; NEOPLASMS; PYRUVATE KINASE; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84856913587     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111487     Document Type: Article

References (32)

1. Akinc, A., A. Zumbuehl, M. Goldberg, E.S. Leshchiner, V. Busini, N. Hossain, S.A. Bacallado, D.N. Nguyen, J. Fuller, R. Alvarez, et al. 2008. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26:561-569. http://dx.doi.org/10.1038/nbt1402
2. Ashizawa, K., M.C. Willingham, C.M. Liang, and S.Y. Cheng. 1991. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem. 266:16842-16846.
3. Bonnet, S., S.L. Archer, J. Allalunis-Turner, A. Haromy, C. Beaulieu, R. Thompson, C.T. Lee, G.D. Lopaschuk, L. Puttagunta, S. Bonnet, et al. 2007. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11:37-51. http://dx.doi.org/10.1016/j.ccr.2006.10.020
4. Boxer, M.B., J.K. Jiang, M.G. Vander Heiden, M. Shen, A.P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C.P. Austin, H.W. Park, et al. 2010. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 53:1048-1055. http://dx.doi.org/10.1021/jm901577g
5. Christofk, H.R., M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, and L.C. Cantley. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230-233. http://dx.doi.org/10.1038/nature06734
6. Christofk, H.R., M.G. Vander Heiden, N. Wu, J.M. Asara, and L.C. Cantley. 2008. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 452:181-186. http://dx.doi.org/10.1038/nature06667
7. Clower, C.V., D. Chatterjee, Z. Wang, L.C. Cantley, M.G. Vander Heiden, and A.R. Krainer. 2010. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. USA. 107:1894-1899. http://dx.doi.org/10.1073/pnas.0914845107
8. David, C.J., M. Chen, M. Assanah, P. Canoll, and J.L. Manley. 2010. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 463:364-368. http://dx.doi.org/10.1038/nature08697
9. DeBerardinis, R.J., J.J. Lum, G. Hatzivassiliou, and C.B. Thompson. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11-20. http://dx.doi.org/10.1016/j.cmet.2007.10.002
10. Dombrauckas, J.D., B.D. Santarsiero, and A.D. Mesecar. 2005. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 44:9417-9429. http://dx.doi.org/10.1021/bi0474923
11. Ferguson, E.C., and J.C. Rathmell. 2008. New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem. Sci. 33:359-362. http://dx.doi.org/10.1016/j.tibs.2008.05.006
12. Goldberg, M.S., D. Xing, Y. Ren, S. Orsulic, S.N. Bhatia, and P.A. Sharp. 2011. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc. Natl. Acad. Sci. USA. 108:745-750. http://dx.doi.org/10.1073/pnas.1016538108
13. Guo, W., Y. Zhang, T. Chen, Y. Wang, J. Xue, Y. Zhang, W. Xiao, X. Mo, and Y. Lu. 2011. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J. Cancer Res. Clin. Oncol. 137:65-72. http://dx.doi.org/10.1007/s00432-010-0860-5
14. Hornung, V., M. Guenthner-Biller, C. Bourquin, A. Ablasser, M. Schlee, S. Uematsu, A. Noronha, M. Manoharan, S. Akira, A. de Fougerolles, et al. 2005. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263- 270. http://dx.doi.org/10.1038/nm1191
15. Huang, Y.H., Y. Bao, W. Peng, M. Goldberg, K. Love, D.A. Bumcrot, G. Cole, R. Langer, D.G. Anderson, and J.A. Sawicki. 2009. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. USA. 106:3426-3430. http://dx.doi.org/10.1073/pnas.0813348106
16. Jackson, A.L., J. Burchard, D. Leake, A. Reynolds, J. Schelter, J. Guo, J.M. Johnson, L. Lim, J. Karpilow, K. Nichols, et al. 2006. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA. 12:1197-1205. http://dx.doi.org/10.1261/rna.30706
17. Jurica, M.S., A. Mesecar, P.J. Heath, W. Shi, T. Nowak, and B.L. Stoddard. 1998. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 6:195-210. http://dx.doi.org/10.1016/S0969-2126(98)00021-5
18. Kleinman, M.E., K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J.Z. Baffi, R.J. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, et al. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 452:591-597. http://dx.doi.org/10.1038/nature06765
19. Lee, J., H.K. Kim, Y.M. Han, and J. Kim. 2008. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 40:1043-1054. http://dx.doi.org/10.1016/j.biocel.2007.11.009
20. Love, K.T., K.P. Mahon, C.G. Levins, K.A. Whitehead, W. Querbes, J.R. Dorkin, J. Qin, W. Cantley, L.L. Qin, T. Racie, et al. 2010. Lipidlike materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. USA. 107:1864-1869. http://dx.doi.org/10.1073/pnas.0910603106
21. Mazurek, S. 2011. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43:969- 980. http://dx.doi.org/10.1016/j.biocel.2010.02.005
22. Michelakis, E.D., G. Sutendra, P. Dromparis, L. Webster, A. Haromy, E. Niven, C. Maguire, T.L. Gammer, J.R. Mackey, D. Fulton, et al. 2010. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2:31ra34. http://dx.doi.org/10.1126/scitranslmed.3000677
23. Noguchi, T., H. Inoue, and T. Tanaka. 1986. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 261:13807-13812.
24. Semenza, G.L. 2011. Regulation of Metabolism by Hypoxia-Inducible Factor 1. Cold Spring Harb. Symp. Quant. Biol. In press. http://dx.doi.org/10.1101/sqb.2011.76.010678
25. Shi, H.S., D. Li, J. Zhang, Y.S. Wang, L. Yang, H.L. Zhang, X.H. Wang, B. Mu, W. Wang, Y. Ma, et al. 2010. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 101:1447-1453. http://dx.doi.org/10.1111/j.1349-7006.2010.01562.x
26. Ugurel, S., N. Bell, A. Sucker, A. Zimpfer, W. Rittgen, and D. Schadendorf. 2005. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int. J. Cancer. 117:825-830. http://dx.doi.org/10.1002/ijc.21073
27. Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029-1033. http://dx.doi.org/10.1126/science.1160809
28. Vander Heiden, M.G., H.R. Christofk, E. Schuman, A.O. Subtelny, H. Sharfi, E.E. Harlow, J. Xian, and L.C. Cantley. 2010a. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79:1118-1124. http://dx.doi.org/10.1016/j.bcp.2009.12.003
29. Vander Heiden, M.G., J.W. Locasale, K.D. Swanson, H. Sharfi, G.J. Heffron, D. Amador-Noguez, H.R. Christofk, G. Wagner, J.D. Rabinowitz, J.M. Asara, and L.C. Cantley. 2010b. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 329:1492-1499. http://dx.doi.org/10.1126/science.1188015
30. Wang, E.T., R. Sandberg, S. Luo, I. Khrebtukova, L. Zhang, C. Mayr, S.F. Kingsmore, G.P. Schroth, and C.B. Burge. 2008a. Alternative isoform regulation in human tissue transcriptomes. Nature. 456:470-476. http://dx.doi.org/10.1038/nature07509
31. Wang, Y., G. Sheng, S. Juranek, T. Tuschl, and D.J. Patel. 2008b. Structure of the guide-strand-containing argonaute silencing complex. Nature. 456:209-213. http://dx.doi.org/10.1038/nature07315
32. Warburg, O. 1956. On the origin of cancer cells. Science. 123:309-314. http://dx.doi.org/10.1126/science.123.3191.309